Bipolar I Disorder

Latest News

FDA-Approved: Risperidone Extended-Release Injectable Suspension
FDA-Approved: Risperidone Extended-Release Injectable Suspension

January 17th 2023

New approval for schizophrenia and bipolar I disorder.

ST.art_AdobeStock
Individualizing Treatment Options in BDI

January 16th 2023

The novel atypical antipsychotic is already FDA-approved for the treatment of schizophrenia in adults.
Positive Phase III Study Results Reported for Bipolar I Disorder Treatment in Adults

December 19th 2022

A Heavy Burden: Bipolar Disorder and Obesity
A Heavy Burden: Bipolar Disorder and Obesity

November 5th 2022

NDA for Long-Acting Injectable for Schizophrenia and Bipolar I Accepted
NDA for Long-Acting Injectable for Schizophrenia and Bipolar I Accepted

September 13th 2022

Video Series
Video Interviews
Podcasts

More News

© 2023 MJH Life Sciences

All rights reserved.